These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
353 related items for PubMed ID: 10770186
1. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P. J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186 [Abstract] [Full Text] [Related]
2. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308 [Abstract] [Full Text] [Related]
3. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P. J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898 [Abstract] [Full Text] [Related]
4. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients. Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P. Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412 [Abstract] [Full Text] [Related]
8. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure. Zhang CF, Liang D, Zhong LY. Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988 [Abstract] [Full Text] [Related]
9. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma. Wémeau JL, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, Jaquet P. J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119 [Abstract] [Full Text] [Related]
10. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N. J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847 [Abstract] [Full Text] [Related]
11. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs. Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G. Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349 [Abstract] [Full Text] [Related]